Enhertu Market Forecast Report Featuring Segment Analysis And Strategic Industry Insight

The Business Research Company's Enhertu Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, July 14, 2026 /EINPresswire.com/ -- Enhertu market to surpass $16 billion in 2030. In comparison, the Oncology Drugs market, which is considered as its parent market, is expected to be approximately $441 billion by 2030, with Enhertu to represent around 4% of the parent market. Within the broader Pharmaceuticals industry, which is expected to be $2,496 billion by 2030, the Enhertu market is estimated to account for nearly 1% of the total market value.



Enhertu Market Report 2026 Regions



Enhertu Market Report 2026 Segments

Which Will Be The Biggest Region In The Enhertu Market In 2030?
North America will be the largest region in the enhertu market in 2030, valued at $7.9 billion. The market is expected to grow from $3.8 billion in 2025 at a compound annual growth rate (CAGR) of 16%. The rapid growth can be attributed to the increasing adoption of targeted oncology therapies across major cancer treatment centers, expanding eligibility of HER2-directed therapies across multiple tumor indications, rising incidence of HER2-expressing cancers, strong clinical uptake supported by evolving treatment protocols, and increasing investments in precision medicine infrastructure and biomarker testing capabilities across the region.

Which Will Be The Largest Country In The Global Enhertu Market In 2030?
The USA will be the largest country in the enhertu market in 2030, valued at $3.5 billion. The market is expected to grow from $1.9 billion in 2025 at a compound annual growth rate (CAGR) of 13%. The rapid growth can be attributed to increasing utilization of antibody-drug conjugates in oncology treatment pathways, expanding access to advanced molecular diagnostics supporting patient identification, growing demand for personalized cancer therapies, continuous clinical evidence generation supporting broader physician confidence, and strong presence of specialized oncology networks accelerating adoption of novel cancer therapeutics.



Enhertu Market Report 2026 Drivers

Request A Free Sample Of The Enhertu Market Report
https://www.thebusinessresearchcompany.com/sample_request?id=20057&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Jul_PR

What Will Be The Largest Segment In The Enhertu Market In 2030?
The enhertu market is segmented by indication into HER2-positive metastatic breast cancer, HER2-low metastatic breast cancer, HER2-mutant non-small cell lung cancer (NSCLC), and HER2-positive metastatic gastric cancer. The HER2-low metastatic breast cancer market will be the largest segment of the enhertu market segmented by indication, accounting for 57% or $9 billion of the total in 2030. The HER2-low metastatic breast cancer market will be supported by the expanding clinical recognition of HER2-low expression as a distinct therapeutic category, increasing biomarker-driven patient stratification initiatives, rising diagnosis rates supported by advanced pathology testing capabilities, growing preference for targeted treatment approaches with broader patient applicability, and continuous expansion of treatment adoption across oncology practice settings.

The enhertu market is segmented by treatment line into first-line therapy, second-line therapy, and third-line therapy.

The enhertu market is segmented by distribution channel into hospital pharmacies, specialty pharmacies, and retail pharmacies.

What Is The Expected CAGR For The Enhertu Market Leading Up To 2030?
The expected CAGR for the enhertu market leading up to 2030 is 18%.

What Will Be The Growth Driving Factors In The Global Enhertu Market In The Forecast Period?

The rapid growth of the global Enhertu market leading up to 2030 will be driven by the following key factors that are expected to expand utilization across multiple HER2-targeted indications, strengthen physician preference through superior clinical outcomes, and increase identification of eligible patients through growing HER2 biomarker testing and cancer screening programs.

Expanding Label Approvals Across Multiple HER2-Targeted Indications - The expanding label approvals across multiple HER2-targeted indications are expected to become a key growth driver for the enhertu market by 2030. Regulatory expansion into broader tumor categories is increasing the eligible patient population and strengthening treatment utilization across oncology settings. As clinical development programs continue to validate therapeutic potential across multiple HER2-expressing cancers, healthcare providers are integrating broader targeted treatment pathways into clinical practice. Pharmaceutical companies are therefore increasing focus on lifecycle expansion strategies to maximize therapeutic reach. This expansion across HER2-targeted indications is reinforcing sustained market growth. As a result, expanding label approvals across multiple HER2-targeted indications is anticipated to contribute approximately 2.6% annual growth to the market.

Superior Clinical Outcomes Compared To Conventional HER2 Therapies - Superior clinical outcomes compared to conventional HER2 therapies are expected to emerge as a major factor driving the expansion of the enhertu market by 2030. Improved efficacy profiles and stronger clinical performance are influencing physician treatment preferences across oncology practice settings. Enhanced progression management capabilities and durable treatment responses are contributing to broader adoption patterns among eligible patient populations. Clinical differentiation is also strengthening competitive positioning within targeted oncology treatment landscapes. Consequently, superior clinical outcomes compared to conventional HER2 therapies are projected to contribute around 2.4% annual growth to the market.

Rising Global Cancer Burden And Increasing HER2 Biomarker Testing - Rising global cancer burden and increasing HER2 biomarker testing are expected to act as a key growth catalyst for the enhertu market by 2030. Expanding oncology screening capabilities and growing biomarker assessment utilization are improving identification rates of HER2-expressing tumors across healthcare systems. Diagnostic advancements are enabling more precise patient selection approaches while supporting broader implementation of biomarker-driven treatment strategies. Improvements in cancer detection infrastructure are further strengthening targeted oncology adoption globally. Therefore, rising global cancer burden and increasing HER2 biomarker testing are projected to contribute approximately 2.2% annual growth to the market.

Access The Detailed Enhertu Market Report Here:
https://www.thebusinessresearchcompany.com/report/enhertu-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Jul_PR

What Are The Key Growth Opportunities In The Enhertu Market In 2030?
The most significant growth opportunities are anticipated in the HER2-positive metastatic breast

cancer market, the HER2-low metastatic breast cancer market, the HER2-mutant non-small cell lung cancer (nsclc) market, and the HER2-positive metastatic gastric cancer market. Collectively, these segments are projected to contribute over $10 billion in market value by 2030, driven by expanding adoption of biomarker-directed oncology therapies, increasing integration of precision treatment approaches across cancer care pathways, growing utilization of companion diagnostic technologies, and continuous advancements in targeted oncology treatment development. This momentum reflects the oncology industry's focus on improving therapeutic precision, expanding personalized medicine capabilities, and strengthening targeted cancer treatment ecosystems, accelerating growth across the global enhertu market.

The HER2-positive metastatic breast cancer market is projected to grow by $2 billion, the HER2-low metastatic breast cancer market by $6 billion, the HER2-mutant non-small cell lung cancer (NSCLC) market by $1 billion, and the HER2-positive metastatic gastric cancer market by $1 billion over the next five years from 2025 to 2030.

What's new in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables

Learn More About [The Business Research Company]
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 30,000+ reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Contact Us:
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company"

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
